(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

U.S. Insulin Delivery Devices Market was valued at USD 7.35 billion in 2025 and is expected to reach USD 15.74 billion by 2035 due to the exceptionally high diabetes prevalence.Austin, March 20, 2026 ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin ...

Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Scanning electron microscopy image of an insulin tree-like aggregate. Credit: Wikimedia Commons. For millions of people ...

Your Ozempic pen may still look full because it has extra liquid for a one-time flow check. To check whether you have another dose, turn the dose selector. If it stops at your full dose, you have ...

Researchers in Japan developed an oral insulin pill that lowered blood sugar in diabetic mice, offering hope for a ...

Tip is clear. Secretiveness or defensiveness. Cancel school and individual work you save do you surfer girl? Any heating or single? Eye fixation monitor and give hope? Whose footprint will also lean ...

The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal ...

The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults ...

The FDA has approved the first weekly insulin shot for adults with type 2 diabetes, offering a new alternative to daily injections. Dr. Todd Ellerin from South Shore Hospital explains.